MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients

MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients

BackgroundThis study aimed to identify microRNAs (miRs) as circulating biomarkers of resistance to first-line trastuzumab-based therapy in advanced HER2-positive oesophago-gastric cancer patients.MethodsA high-throughput 1015 Exiqon miRCURY LNA™ microRNA inhibitor library screen was performed in tra...

Full description

Bibliographic Details
Main Authors:	Hazel Lote, Florentia Mousoullou, George Vlachogiannis, Andrea Lampis, Laura Satchwell, Clare Peckitt, Caroline Fong, Ruwaida Begum, Shannon Kidd, Susan Cromarty, Anderley Gordon, Charlotte Fribbens, Sheela Rao, Naureen Starling, Ian Chau, David Cunningham, Nicola Valeri
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Series:	Frontiers in Oncology
Subjects:	oesophageal adenocarcinoma gastric cancer microRNA HER2 biomarkers trastuzumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1258365/full

Similar Items

Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma
by: Ali Abdulnabi Suwaidan, et al.
Published: (2022-01-01)

Double stenting for malignant oesophago-respiratory fistula
by: Janusz Włodarczyk, et al.
Published: (2016-08-01)

The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review
by: Nikhil Manish Patel, et al.
Published: (2023-11-01)

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
by: Anica Högner, et al.
Published: (2021-02-01)

Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
by: Zhou Qiong, et al.
Published: (2020-07-01)

Feasibility of Implementation and the Impact of a Digital Prehabilitation Service in Patients Undergoing Treatment for Oesophago-Gastric Cancer
by: Krishna Moorthy, et al.
Published: (2023-01-01)

Trastuzumab and ECG Changes Dilemma
by: Azin Alizadehasl, et al.
Published: (2023-04-01)

Trastuzumab Cures Cancer and Disrupts the Practice of Cardiology∗
by: Richard M. Steingart, MD, et al.
Published: (2019-09-01)

ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS)
by: JV Reynolds, et al.
Published: (2017-06-01)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
by: Baubek Spanov, et al.
Published: (2022-01-01)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla
by: Wiesław Guz, et al.
Published: (2024-01-01)

Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population
by: Fan Yang, et al.
Published: (2020-03-01)

Enalapril más Carvedilol en la prevención de la cardiotoxicidad por antraciclinas y/o trastuzumab
by: Daysi Luperon Loforte, et al.
Published: (2020-07-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
by: Cara Ghiglieri, et al.
Published: (2023-10-01)

Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis
by: Xinyi Li, et al.
Published: (2021-08-01)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
by: Wei‐Ting Chang, et al.
Published: (2021-12-01)

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity
by: Darryl P. Leong, MBBS, MPH, MBiostat, PhD, et al.
Published: (2019-09-01)

Interstitial Pneumonitis Secondary to Trastuzumab: A Case Report and Literature Review
by: Ricardo Costa, et al.
Published: (2017-06-01)

First reported case of ANCA-associated vasculitis induced by oxaliplatin, capecitabine, and trastuzumab
by: Bengang Huo, et al.
Published: (2023-12-01)

Effectiveness of adjuvant trastuzumab in daily clinical practice
by: Matos Erika, et al.
Published: (2014-12-01)

Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor
by: Katia Cortese, et al.
Published: (2023-05-01)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023-02-01)

Trastuzumab for HER-2-Positive Advanced Salivary Gland Cancer
by: Yi-Tsung Yang, et al.
Published: (2014-12-01)

Olası Trastuzumab Kullanımına Bağlı Gelişen Pyojenik Granülom
by: Hilmi Cevdet Altınyazar, et al.
Published: (2013-01-01)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
by: Hiromichi Nakajima, et al.
Published: (2022-02-01)

Trastuzumab immunogenicity development in patients’ sera and in laboratory animals
by: Lobna Abdel Aziz Kilany, et al.
Published: (2021-02-01)

Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
by: Ioannis A. Vathiotis, et al.
Published: (2023-02-01)

A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
by: Erika Matos, et al.
Published: (2016-01-01)

A remarkable clinical response in advanced gastric cancer treated with trastuzumab plus capecitabine combination chemotherapy: A report of two cases
by: Naohiko Nakamura, et al.
Published: (2019-04-01)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
by: Iacopo Fabiani, et al.
Published: (2020-08-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
by: E. V. Lubennikova, et al.
Published: (2017-11-01)

Trastuzumab administration during pregnancy: un update
by: Angeliki Andrikopoulou, et al.
Published: (2021-04-01)

Efficacy and safety of short course adjuvant trastuzumab combination chemotherapy in breast cancer
by: Sachin S Hingmire, et al.
Published: (2017-01-01)

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
by: Holden Eaton, et al.
Published: (2023-04-01)

Coexistence of Gastric Adenocarcinoma and Choriocarcinoma: Complete Response to Trastuzumab and Chemotherapy
by: Seyda Gunduz, et al.
Published: (2012-07-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022-12-01)